Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Kushen Injection for prevention of radiotherapy-related adverse reactions in head and neck cancer
ChiCTR-IPR-14005481Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Oct 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound kushen injection in head and neck cancer (HNC) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Incidence and severity of radiotherapy-related adverse reactions. Started Oct 2014; status: recruiting.
02
Drugs
compound kushen injection
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on ChiCTR-IPR-14005481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005481.